Allogeneic Alternatives to Autologous Bone Marrow: The MSC Clinical Trials of Acute MI with MSCs

Research output: Chapter in Book/Report/Conference proceedingChapter


The regenerative properties of mesenchymal stem cells (MSCs) are undergoing active investigation as a therapeutic principle for cardiovascular disease. Initial studies using autologous cells provide a solid foundation for the field. Given the immunoprivileged properties of these cells, Phase I and II clinical trials for ischemic cardiomyopathy have shown that allogeneic cell therapy is equally safe and effective. The concerns that allogeneic cells would produce neoplasia, immune responses, or episodes of arrhythmia have not been borne out. Currently, a variety of MSC preparations are undergoing Phase III trials. Several mechanistic studies show that MSCs decrease myocardial scar tissue and enhances left ventricular function. Together this body of work suggests that this approach is a novel, cost-effective, off-the-shelf therapy that may improve cardiac performance and quality of life in patients with ischemic and nonischemic cardiovascular pathologies.

Original languageEnglish (US)
Title of host publicationStem Cell and Gene Therapy for Cardiovascular Disease
PublisherElsevier Science Ltd.
Number of pages11
ISBN (Electronic)9780128018637
ISBN (Print)9780128018880
StatePublished - Jan 1 2015


  • Acute myocardial infarction
  • Allogeneic
  • Clinical trials
  • Ischemic cardiac pathology
  • Mesenchymal stem cells

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Allogeneic Alternatives to Autologous Bone Marrow: The MSC Clinical Trials of Acute MI with MSCs'. Together they form a unique fingerprint.

Cite this